SCHEMBL4282403

SCHEMBL4282403

Cc1cc(CCCO)ccn1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
UHRF1 Q96T88 1/20 0.43
CYP4A11 Q02928 3/20 0.41
CYP4F2 P78329 2/20 0.41
KCNQ2 O43526 1/20 0.40
GSK3A P49840 2/20 0.38
GSK3B P49841 2/20 0.38
FFAR1 O14842 1/20 0.38
RECQL P46063 1/20 0.37
TNKS2 Q9H2K2 1/20 0.36
NR3C2 P08235 2/20 0.36
GRM5 P41594 1/20 0.35
LTA4H P09960 1/20 0.35
EPHX2 P34913 1/20 0.35
CA2 P00918 1/20 0.34
IGF1R P08069 1/20 0.34
ALOX15 P16050 1/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
P2RY12 Q9H244 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258739 0.93 BCHE (0.41) UHRF1CYP4A11CYP4F2KCNQ2GSK3A
SCHEMBL30324476 0.88 UHRF1 (0.46) UHRF1CYP4A11CYP4F2KCNQ2GSK3A
SCHEMBL2023682 0.88 UHRF1 (0.46) UHRF1CYP4A11CYP4F2KCNQ2GSK3A
SCHEMBL4358691 0.88 UHRF1 (0.50) UHRF1KCNQ2GSK3AGSK3BFFAR1
SCHEMBL4355540 0.83 UHRF1 (0.54) UHRF1KCNQ2GSK3AGSK3BFFAR1
SCHEMBL9402852 0.82 SKP2 (0.47) UHRF1KCNQ2GSK3AGSK3BALOX15
SCHEMBL13573929 0.81 UHRF1 (0.43) UHRF1KCNQ2GSK3AGSK3BFFAR1
SCHEMBL12288701 0.81 HRH1 (0.46) UHRF1KCNQ2GSK3AGSK3B
Bromide SCHEMBL5762760 0.81 SKP2 (0.46) UHRF1KCNQ2GSK3AGSK3BALOX15
SCHEMBL26944235 0.81 UHRF1 (0.43) UHRF1KCNQ2GSK3AGSK3BFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115151550-B External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof 桑福德·伯纳姆·普雷比医学发现研究所 2024-11-22 CN disclosed
CN-112566906-B Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4 多曼治疗学公司 2024-11-12 CN disclosed
US-20230121698-A1 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2023-04-20 US disclosed
EP-4081528-A1 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2022-11-02 EP disclosed
CN-115151550-A Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof 桑福德·伯纳姆·普雷比医学发现研究所 2022-10-04 CN disclosed
US-20220089609-A1 SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 DOMAIN THERAPEUTICS (FR) 2022-03-24 US disclosed
WO-2021133915-A1 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2021-07-01 WO disclosed
WO-2021133915-A1 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2021-07-01 WO disclosed
EP-3827001-A1 SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 Domain Therapeutics (FR) 2021-06-02 EP disclosed
CN-112566906-A Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4 多曼治疗学公司 2021-03-26 CN disclosed
WO-2020021064-A1 SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 DOMAIN THERAPEUTICS (FR) 2020-01-30 WO disclosed
WO-2020021064-A1 SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 DOMAIN THERAPEUTICS (FR) 2020-01-30 WO disclosed
WO-2009153536-A1 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2009-12-23 WO disclosed
WO-2009154555-A1 PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA2-ADRENOCEPTOR AGONIST ASTRAZENECA AB (SE) 2009-12-23 WO disclosed
WO-2009154554-A1 PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT ASTRAZENECA AB (SE) 2009-12-23 WO disclosed
US-5763461-A ANTIPICORNAVIRAL AGENTS SANOFI (FR) 1998-06-09 US disclosed
US-5618821-A VIRICIDES, PICORNAVIRUS SANOFI, S.A. (FR) 1997-04-08 US disclosed
WO-1995031438-A1 THERAPEUTIC PHENOXYALKYLHETEROCYCLES SANOFI WINTHROP, INC. (US) 1995-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230121698-A1 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF ENPP1, ENPP3, PPA1 UHRF1 3654/4885CYP4A11 2772/4885CYP4F2 3454/4885
US-20220089609-A1 SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 GRIK4, GRM4, GRIA4 UHRF1 3342/4885CYP4A11 1542/4885CYP4F2 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.